Hemostasis Today

October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Mohamed Magdy: Essential Thrombocythemia Summary
Oct 11, 2026, 14:29

Mohamed Magdy: Essential Thrombocythemia Summary

Mohamed Magdy, Wound Care Consultant at Armed Force Rehabilitation Center, posted on LinkedIn:

“Essential Thrombocythemia (ET) Summary

Definition:

  • Chronic myeloproliferative neoplasm (MPN).
  • Characterized by persistent overproduction of platelets due to abnormal megakaryocytes in the bone marrow.

Pathophysiology:

  • Clonal proliferation of megakaryocytes high platelet production.
  • Main mutations:

JAK2 V617F (50 to 60 percent)
CALR (20 to 30 percent)
MPL (5 to 10 percent )

Clinical Features:

Thrombosis:

  • Stroke  TIA
  • Myocardial infarction
  • DVT PE
  • Microvascular symptoms:
    Headache
    Visual disturbances
    Erythromelalgia (burning pain and redness of hands or feet)

Bleeding:

  • Easy bruising
  • Mucosal bleeding
  • GI bleeding (especially with very high platelet counts)

Diagnosis:

  • Persistent platelets 450 10⁹L
  • Bone marrow: increased abnormal megakaryocytes
  • JAK2  CALR MPL mutation testing
  • Exclude reactive thrombocytosis and other MPNs

Risk Stratification:

Low risk:
• Age low 60 years
• No previous thrombosis

High risk:

  • Previous thrombosis
  • Age high 60 years
  • JAK2 mutation with risk factors

Treatment:

Low risk:

Observation plus or minus low dose aspirin (if indicated)

High risk:

Cytoreductive therapy:
Hydroxyurea (first line)
Interferon α (alternative, especially younger patients or pregnancy)

Aspirin when appropriate for prevention of microvascular symptoms or thrombosis.

High Yield Points:

ET equal MPN with high platelets
Most common mutation equal JAK2 V617F
Main complications equal Thrombosis plus Bleeding”Mohamed Magdy: Essential Thrombocythemia Summary

Stau updated with Hemostasis Today.